JW Pharmaceutical Corporation

KSE 001060.KS

JW Pharmaceutical Corporation Current Liabilities for the year ending December 31, 2023: USD 220.36 M

JW Pharmaceutical Corporation Current Liabilities is USD 220.36 M for the year ending December 31, 2023, a -26.62% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

JW Pharmaceutical Corporation Current Liabilities for the year ending December 31, 2022 was USD 300.30 M, a 26.92% change year over year.
JW Pharmaceutical Corporation Current Liabilities for the year ending December 31, 2021 was USD 236.60 M, a 9.79% change year over year.
JW Pharmaceutical Corporation Current Liabilities for the year ending December 31, 2020 was USD 215.50 M, a -10.07% change year over year.
JW Pharmaceutical Corporation Current Liabilities for the year ending December 31, 2019 was USD 239.62 M, a 17.37% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

KSE: 001060.KS

JW Pharmaceutical Corporation

CEO	Mr. Young-Sub Shin
IPO Date	Sept. 29, 2005
Location	South Korea
Headquarters	2477, Nambusunhwan-ro
Employees	1,064
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

JW Pharmaceutical Corporation develops, manufactures, and sells medicines and medical supplies in Japan and internationally. It offers products in the areas of cardiovascular, gastrointestinal, urinary, oral hypoglycemic, antibiotics, anti-fungal, Ob and Gy, renal, CNS, anti-anemic, respiratory, rheumatic arthritis, anticancer, anesthetic, antidotes, amino acids, TPN, and others. The company was founded in 1945 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years